G1 Therapeutics

G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It is also advancing rintodestrant, a potential oral selective estrogen receptor degrader, or serd, for the treatment of er+ breast cancer. It is committed to improving the lives of those impacted by cancer. It is also executing a tumor-agnostic development program, with late-stage clinical trials ongoing in multiple tumor types.

G1 Therapeutics headquartered in United States, North America, operates in the Biotechnology, Medical, Developer Platform, Therapeutics, Oncology sector. The company focuses on Biotechnology and has secured $139.5B in funding across 200 round(s). With a team of 51-100 employees, G1 Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Debt Financing - G1 Therapeutics, raised $457.9K. Discover more about their projects, partnerships, and impact on our platform.